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Antitumor activity of polysaccharide PST001 isolated from the seed kernel of Tamarindus indica was evaluated using diﬀerent
cancer cell lines. Human cancer cell lines A549, KB, and MCF-7 and murine cancer cell lines DLA and EAC were treated with
PST001 and cell growth inhibition was assessed by MTT assay. In vivo studies were carried out for toxicity, tumor reduction
and immunomodulation. The respective IC50 of PST001 in A549, KB, and DLA was at 80.72, 190.99, and 91.14µg/mL. Signiﬁcant
tumor reduction was obtained in both DLA and EAC tumors on treatment with PST001 which was more prominent when PST001
wasadministeredwithCTX/5-ﬂuorouracil.IncreaseintotalWBC,CD4+ T-cellpopulation,andbonemarrowcellularitysuggested
strong immunomodulatory activity for this compound. No signiﬁcant abnormality was observed in toxicity studies. Thus the
results of the present study suggest that PST001 has immunomodulatory and tumor inhibitory activities and has the potential to
be developed as an anticancer agent and immunomodulator either as a sole agent or as an adjuvant to other chemotherapeutic
drugs.
1.Introduction
Cancer is the leading cause of mortality worldwide and
most of the chemotherapeutic agents have been reported
to exhibit severe toxicity to normal tissues, accompanied by
undesirable side eﬀects. Moreover, most of these drugs are
highly expensive, mutagenic, and carcinogenic. Therefore,
novel pharmaceutical agents that provide a more speciﬁc
treatment regimen or increase the eﬃcacy of conventional
chemotherapy, without increasing toxicity towards normal
cells, would clearly be of immense clinical beneﬁt. This can
be achieved by in-depth research and continuous screening
of new molecules or natural agents which will provide new
compounds with potential to be developed as antitumour
drugs. Indian traditional system of medicine uses plant-
derivedmedicinesinhealthcarefromancientperiodoftime.
However, the active components involved and their mech-
anisms of action remain undeﬁned [1]. Although mono-
therapy was advocated at one time, recent experiences indi-
cate that agents that target multiple pathways have more po-
tential in cancertreatment. This understanding has led to the
genesis of combination therapy.
Naturalproductshavebeenthemainstayofcancerchem-
otherapy for the past 30 years and are likely to provide
many of the lead structures, and these will be used as tem-
plates for the construction of novel compounds with en-
hanced biological properties [2]. Nearly 60% of the current
anticancer compounds are derived from natural products or
their derivatives.
Current research area concentrates heavily on anticancer
drug development from natural products with special
emphasis on biopolymers like polysaccharides. Numerous
studies suggest that certain plant polysaccharides might be
useful as anticancer and chemopreventive agents.
ComponentsofTamarindusindica(Ti),awidelygrowing
tree in India and South East Asia, have found place in human
lifeasaspice,foodcomponent,andsnack.TheseedsofTiare
used as an anthelmintic, antidiarrheal, and an emetic agent,2 The Scientiﬁc World Journal
and the seed coat is used to treat burns and aid in wound
healing as well as an antidysenteric agent [3].
Tamarind seed polysaccharide possesses properties such
as high viscosity, broad pH tolerance, and adhesive and these
have led to its application as stabilizer, thickener, gelling
agent, and binder in food and pharmaceutical industries [4].
This has also been used as artiﬁcial tear in modern medicine
[5]. In our earlier studies, we have reported the preliminary
results on immunomodulatory and antiproliferative activi-
ties of the polysaccharide (PST001) isolated from the seed
kernel of Ti [6, 7].
Polysaccharides represent a structurally diverse class
of macromolecules of relatively widespread occurrence in
nature.Unlike proteins and nucleic acids, they containrepet-
itive structural features, which are polymers of monosac-
charide residues joined to each other by glycosidic linkages.
Among the macromolecules, polysaccharides oﬀer the high-
est capacity for carrying biological information because they
havethegreatestpotentialforstructuralvariability.Although
their ubiquitous role in biological processes and their ver-
satility as biocompatible, environmentally friendly materials
are beyond doubt, polysaccharides are still considered to be
the “sleeping giant” of biotechnology.
The mechanisms of cell death induced by drugs are a
much required aspect of drug research. Plants exert anti-
tumor eﬀects through various mechanisms which include
direct cytotoxicity and through immunopotentiation of
immune eﬀector cells. Immunomodulators are well known
for their antitumor activity and polysaccharides are very
proﬁcient immunomodulators, supporting the demand for
further research into this compound. The targets of action
of this plant product and its toxic eﬀects also need to be
understood before clinical trials are carried out. Hence, this
study has evaluated the in vivo and in vitro eﬀects of PST001
on cancer cells. The results suggest this polysaccharide to
possess strong immunomodulatory activities and antitu-
mour functions in mice.
2.MaterialsandMethods
2.1.Chemicals. Dulbecco-ModiﬁedEagleMedium(DMEM)
and RPMI 1640 were purchased from Gibco Invitrogen Cor-
poration, USA; antibiotics (Penicillin, Streptomycin and
Amphotericin) were obtained from Lonza India PVT Ltd.
Mumbai, India; Ficoll-paque was from Pharmacia Fine
Chemicals,Uppsala,Sweden;fetalcalfserum(FCS)wasfrom
Pan Biotech GmbH; MTT and PHA were from Sigma-Al-
drich Co., St. Louis, MO, USA; FITC-conjugated mouse mo-
noclonal antibodies anti-CD3, anti-CD4, and anti-CD8 were
purchased from BD Biosciences, San Jose, CA, USA.
2.2. Isolation and Puriﬁcation of the Polysaccharide PST001.
Seed kernel of Tamarindus indica was collected and shade
dried.Hundredgramsofpowderedseedkernelwasextracted
with petroleum ether (BP 60◦–80◦C) at room temperature
for 72 hours with occasional stirring in order to remove
any fat present in it. The dried material was extracted
with distilled water using a soxhlet apparatus. The aqueous
extract was centrifuged at 20,000×g for 15 minutes, and
polysaccharide was precipitated with ethanol with constant
stirring and kept overnight at 4◦C to complete the precip-
itation of polysaccharide. The precipitate was pelleted by
centrifugation at 20,000×g for 15min, and the residue was
dissolved in distilled water. It was treated with equal volume
of chloroform in a separating funnel, and the denatured
protein formed as a gel at the water chloroform interphase
was removed and the process was repeated till the interphase
became clear. This was followed by dialysis against distilled
w a t e rf o r4 8h o u r sa ts e v e r a lc h a n g e so fw a t e r .T h ec o n t e n t s
of dialysis bags were collected, concentrated, and treated
with ethanol to precipitate the polysaccharide. Precipitate
was collected by centrifugation at 20,000×g, and the residue
wasdissolvedindistilledwater(100mL)anddialyzedagainst
distilled water, concentrated, and lyophilized. This was
puriﬁed by gel ﬁltration chromatography using Sephadex G-
200 (Pharmacia Fine Chemicals); 0.001M PBS was used as
the eluent, ﬁnally lyophilized and stored at −20◦C.
2.3. Cell Lines. The following cell lines were used: A549,
human lung adenocarcinoma cell line; KB, a human oral
cancer cell line; and MCF-7, a human breast cancer cell
line, were purchased from National Centre for Cell Science
(NCCS, Pune, India). DLA (Dalton lymphoma ascites) and
EAC (Ehrlich ascites carcinoma), which are murine lym-
phoid cancer cell lines, were obtained under the courtesy of
Amala Cancer Research Center, Thrissur, Kerala, India, and
weremaintainedbyweeklyintraperitonealinoculationof106
cells/per mouse. All the human cell lines were maintained
in culture medium (CM) containing Dulbecco-Modiﬁed
Eagle Medium (DMEM) supplemented with 10% fetal calf
serum (FCS), 2mM L-glutamine, and antibiotics (Penicillin,
Streptomycin and Amphotericin). Cells were grown in T-25
culture ﬂasks at 37◦C in a humidiﬁed atmosphere containing
5% CO2 and 95% air.
2.4. Antitumor Activity of PST001
2.4.1. Determination of Cytotoxic Activity of PST001 in
Culture by MTT Assay. Cells were seeded (5000 cells/well)
in 96-well, ﬂat-bottom titer plates and incubated for 24, 48,
and 72 hours at 37◦Ci n5 %C O 2 atmosphere. Diﬀerent
concentrations of PST001 (0.001–1000µg/mL) were added
and incubated further for various time periods. After
completion of incubation, the medium was removed. The
wells were washed with PBS; 100µL of the working MTT dye
in DMEM media was added and incubated for 2 hours. MTT
lysis buﬀer (100µL) was added and incubation continued
for 4hrs more. The absorbance was measured at 570nm and
the proliferation rate (PR) was calculated using the following
formulae:
PR =
Absorbance of Test
Absorbance of Control
×100. (1)
Cytotoxicity of the drug PST001 on the cells was calculated
as cell growth inhibition rate (IR)
IR = 100 − PR. (2)The Scientiﬁc World Journal 3
2.4.2.TumorReduction. MaleSwissalbinomiceweredivided
into four sets of six animals (n = 6) each. EAC/DLA
cells were collected from the donor mouse and were
suspended in sterile isotonic saline. The viable EAC/DLA
cells were counted (Trypan blue indicator) under the
m i c r o s c o p ea n dw e r ea d j u s t e da t1× 106 cells/mL. From
this 0.1mL of DLA/EAC cells per 10g body weight of
the animals was injected intraperitoneally (i.p.). The group
administered with vehicle alone (PBS) was maintained as
control. Cyclophosphamide (CTX) (50mg/kg b.wt., i.p.) was
used as the standard reference drug as reported [8–10]f o r
DLA and 5-FU (20mg/kg b.wt., i.p.) for EAC was used as
the standard reference drug [11]. PST001 (200mg/kg b.wt.;
i.p) and PST + CTX or PST + 5-FU were administered to the
respective groups.
The administration of drugs in the diﬀerent groups was
as shown in Table 1.
2.4.3. Determination of Tumor Volume, Median Survival Time
(MST), and Percentage of Life Span Analysis. On the 15th
and 22nd day of compound/drug administration, animals
were sacriﬁced to determine the tumor volume. Brieﬂy, after
sacriﬁce, the abdomen of each mouse was cleaned oﬀ fur and
incised over a clean vessel. The volume of the ascitic ﬂuid
obtained (V1) was collected in a graduated centrifuge tube.
The peritoneal cavity of the mouse was irrigated thoroughly
with isotonic saline (prevents coagulation of cells) until the
return was clear. The volume of the added saline (V2) was
noted and added to the same graduated tube.
Volume of ascitic tumor (V3) was calculated by sub-
tracting the volume of saline added from the total volume
of ascitic ﬂuid plus saline. V3 = (V1+V2) − V2. The
median survival time (MST) was assessed according to
Geran’s method [12]. MST = (x + y)/2, where x denotes the
earliest day when the number of dead animals is greater than
or equal N/2; y denotes the earliest day when the number of
dead animals is greater than or equal (N/2) + 1; N denotes
the number of animals in the group. The eﬃcacy of the plant
polysaccharide against DLA/EAC (deﬁned as the increment
inlifespan,ILS)wasassessedaccordingto%ILS=(T -C)/C×
100 where T represents median survival time of the treated
animals and C represents the median survival time of the
control group.
2.4.4. Determination of Packed Cell Volume Viable and Non-
viableTumorCellCount. The ascitic ﬂuid was collected from
the peritoneal cavity of the animals and divided into two
parts. One part was centrifuged in a graduated centrifuge
tube at 1,000rpm for 10min and the packed cell volume
(PCV) was measured. The cells in the other part of the
ascitic ﬂuid were separated by centrifugation and stained
with trypan blue (0.4% in normal saline). The viable and
nonviable cells were counted using a Neubauer chamber
(hemocytometer).
2.4.5. Determination of Eﬀect of PST001 on Hematological
Parameters. Blood samples from each animal were collected
by heart puncture for estimation of Hemoglobin (Hb)
content, platelet count, red blood cell count (RBC), and
white blood cell count (WBC). WBC diﬀerential count was
carried out from Leishman stained blood smears [13].
2.5. Evaluation of Immunomodulatory Properties of PST001.
BALB/c mice, 6 in each group (either sex) weighing 25 ± 4g,
were acclimatized to laboratory conditions for 7 days prior
to initiation of dosing. Each animal was assigned a unique
identiﬁcation number and marked with picric acid. PST001
was administered intraperitoneally in graduating doses of
100mg/kg, 200mg/kg, and 400mg/kg body weight for a
period of 14 days. Blood was collected by cardiac puncture
from PST001 treated BALB/c mice on 15th day.
2.5.1. Lymphocyte Proliferation Assay. Lymphocytes isolated
from the blood using ﬁcoll-hypaque gradient centrifugation
were cultured in RPMI-1640 containing 10% FCS and 20µL
of 5mg/mL mitogen phytohemagglutinin (PHA) in 96-well
microtitre plates at 37◦Ci na5 %C O 2 atmosphere for 0hr
and72hr.Therelativeviabilityoflymphocyteswasexamined
by measuring the amount of purple formazan formed by
MTT assay. The experiments were done in triplicate and
absorbance was read at 570nm.
Percentage cell viability is T/C × 100 (whereT is Test OD
and C is Control OD).
2.5.2. Eﬀect of PST001 on Haematological Parameters. For
total count, blood was diluted with Turk’s ﬂuid (1:20) so as
to lyse all the erythrocytes, and leukocytes were loaded on to
the Neubauer haemocytometer. Total white blood cell count
was determined using the following formula:
No. of cells counted ×dilution factor ×depth factor
Area counted
.
(3)
The diﬀerential count of WBC was performed on a
minimum of 200 cells to identify lymphocytes, neutrophils
and eosinophils in the blood smear.
2.5.3. Immunophenotyping by Flow Cytometry. Whole blood
obtained from control and PST001 treated mice was diluted
at a ratio 1:10 with (1X) lysis buﬀer (BD Pharm Lyse) to
lyse the RBCs, mixed well, and incubated for 10min at room
temperature (RT) in the dark. Tubes were centrifuged for
5min at 500×g, supernatant aspirated, cells washed again
with 2mL of sheath ﬂuid (BD FACS Flow, BD Biosciences,
San Jose, USA), and spun down at 200×gf o r5 m i nt o
aspirate the supernatant. Viable cells obtained were adjusted
to a cell concentration of 107/mL in falcon tubes. The cells
were protected from light throughout staining and storage.
CD3, CD4, and CD8 positive cells were determined by
direct immunoﬂuorescence using the following antibodies:
anti-CD3 (FITC), anti-CD4 (PE), and anti-CD8 (PerCp)
purchased from Becton-Dickinson, San Jose, USA. After
incubation for 30 minutes, the cells were washed three times
with sheath ﬂuid and analyzed immediately on a FACS
Calibur (Becton Dickinson, San Jose, USA) for evaluating4 The Scientiﬁc World Journal
Table 1
Group No. of
animals Treatment Day of
administration
Days of
observation
I6 × 4s e t s
(a)Vehicle
11 5 (b) PST001
(c) Reference drug
(d) PST001+ reference drug on
day 1
II 6 × 4s e t s
(a) Vehicle
1–14— every day 15 (b) PST001
(c) Reference drug
(d) PST001+ reference drug
III 6 × 4s e t s
(a) Vehicle
8–21—every day 22 (b) PST001
(c) Reference drug
(d) PST001+ reference drug after
7th day
IV 6 × 4s e t s
Administerd for 7 days
1–7—every day 22
(a) Vehicle
(b) PST001
(c) Reference drug
(d) PST001+ reference drug +
EAC/DLA on day 8
For Group I–Group III; DLA/EAC administered on ﬁrst day. In Group IV; DLA/EAC administered on 8th day.
lymphocyte subsets. Upon ﬂow cytometric analysis, lym-
phocytes were gated according to their forward versus side
scatterpropertiesanddisplayedasdotplots.Foreachsample,
10,000 gated cells were analyzed using BD CellQuest Pro
Software (Becton Dickinson, San Jose, USA).
2.5.4. Eﬀect of PST001 on Bone Marrow Cellularity. After
the experimental period (14 days), mice were sacriﬁced, and
femur bone was collected and cut at the level of epiphyseal
plates of the proximal and distal ends of the femur bone.
RPMI media taken in a syringe were injected gently into one
end of the shaft which ﬂushed the marrow out through the
opposite end into a collection vessel. Three milliliter of air
was aspirated into the syringe and gently pushed through
the femur to remove any media and marrow remaining in
the needle or in the femur. Additional processing provided
a single cell suspension and broken bone spicules. The cell
suspensions obtained were stained, checked for viability
using Trypan blue in a hemocytometer, and expressed as
million cells/femur. Both femora were processed to obtain
two separate samples for a more conﬁdent quantitation
of the cells. To ensure viability of bone marrow cells, it
was conﬁrmed that the freshly dissected femur had both
distal and proximal ends intact and was processed within 10
minutes of death of the animal.
2.6. Toxicity Studies
2.6.1. Acute Toxicity. Inbred female BALB/c mice were
maintained as described earlier and PST001 dissolved in
phosphate buﬀered saline (PBS) was administered intraperi-
toneally in graduating doses of 500mg/kg to 2000mg/kg
body weight to several groups of experimental animals,
one dose being used per group and spaced. Animals were
observed continuously for 2hr, then occasionally for further
4hr, and ﬁnally overnight and mortality was recorded.
Observations of behavior changes were made at 10, 30, 60,
and 120 minutes and at 4 and 6 hours and up to 24 hours.
The weight of mice was recorded and the mean body weights
of the study groups were calculated. At the end of the exper-
iment, surviving animals were weighed, some of them were
sacriﬁced, and the rest were housed in the normal environ-
ment. The dose lethal to ﬁfty percent of mice in experiments
is considered as LD50. All the animal experimentation pro-
cedures described including maintenance were reviewed and
approved by Institutional Animal Ethics Committee accord-
ing to the norms of Committee for the Purpose of Control
and Supervision of Experiments on Animals (CPCSEA,
Ministry of Environment and Forests, Goverment of India).
2.6.2. Subacute Toxicity. T h ed o s e sf o rs u b a c u t es t u d i e sa r e
standardized by selecting appropriate doses from 1/20th
1/10th and 1/5th of LD50 usually, but in our experi-
ments no LD50 was obtained up to a concentration of
2000mg/kg body weight. Therefore, 100mg/kg—1/20th;
200mg/kg—1/10th; 400mg/kg—1/5th were the concentra-
tions of PST001 applied forsubacute toxicity studies. Groups
of 6 mice (3 females and 3 males) were treated with
daily doses of diﬀerent concentrations of PST001 such as
100mg/kg, 200mg/kg, and 400mg/kg body weight/animalThe Scientiﬁc World Journal 5
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Figure 1: (a–e) Cytotoxicity proﬁle of PST001 on human and murine cancer cell lines as measured by MTT assay: (a) A549 (lung adeno
carcinoma), (b) KB (oral cancer), (c) MCF-7 (breast cancer), and (d and e) DLA and EAC (Murine cancer cells). (f–j) Cytotoxicity proﬁle of
positive control drugs on human and murine cancer cell lines as measured by MTT assay: (f) A549 (Cisplatin), (g) KB (Doxorubicin), (h)
MCF-7 (Doxorubicin), (i) DLA (CTX), and (j) EAC (5-Fluro Uracil).
by intraperitoneal injections for 14 consecutive days. Ani-
mals of the vehicle-control group received equal volumes of
PBS. All mice were daily weighed and examined for signs of
toxicity. Animals that died during the treatment period and
those sacriﬁced (by cervical dislocation) 24h after the last
dose or its vehicle were subjected to necropsy. Organs such
as liver, kidney, and spleen were examined for macroscopic
lesions and were ﬁxed in buﬀered formaldehyde solution
(10%) and histopathological examination was conducted
after H&E staining.
2.6.3. Determination of the Eﬀect of PST001 on Biochemical
Parameters. To study the eﬀect of PST001 in mice on
biochemical parameters, blood samples from each animal
were collected by heart puncturing and serum was collected
after centrifugation at 3000rpm for 15 minutes. Biochemical
parameters SGOT (Serum glutamic oxaloacetic transami-
nase)andSGPT(Serumglutamicpyruvictransaminase)and
serum creatinine were measured using standard protocols.
2.7. Statistical Analysis. The results were expressed as the
mean (SD). The diﬀerences between control/PST001-treated
groups were evaluated for statistical signiﬁcance by one-
way analysis of variance (ANOVA) followed by the Tukey-
Kramer multiple-comparison tests. P<0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Antitumor Activity of PST001
3.1.1. Eﬀect of Antiproliferative Activity of PST001 on Cancer
Cell Lines. The in vitro growth inhibition of cancer cells
A549, KB, MCF-7, DLA, and EAC by PST001 is shown in
Figures 1(a)–1(e). Doxorubicin for KB and MCF-7 cells,
Cisplatin for A549, 5-FU for EAC, and CTX for DLA
were included as positive controls for comparison (Figures
1(f)–1(j)). A dose-dependent inhibition of cell proliferation
was observed in A549, KB, and DLA when cells were
incubated with increasing doses of PST001. IC50 values
were determined using Easyplot software and found to be
80.72, 180.99, and 91.14µg/mL for A549, KB, and DLA,
respectively. Signiﬁcant growth inhibition was evident but
no IC50 value was obtained for MCF-7 and EAC at all time
periods.
As is evident from Figures 1(a)–1(e), all the cell lines
showed increasing cytotoxicity at lower concentrations and
reduction at higher concentrations (500–1000µg/mL) of
PST001.
3.2. Tumor Reduction. Mice inoculated with the DLA and
EAC tumors were evaluated on 15th and 22nd days of
PST001administrationfortheeﬀectonbodyweights,tumor
volume, median survival time, and % ILS.
3.2.1. Eﬀect of PST001 on DLA Tumor Bearing Mice. Tumor
volume was estimated and found to be reduced in the treated
mice in all the groups (I, II, III, and IV) (P<0.01).
Body weight was also signiﬁcantly higher in tumor bearing
mice and reduced on PST001 and drug administration
(Figure 2(a)). Packed cell volume and tumor cell counts were
diminished when compared to DLA control in all the three
groups (P<0.01). Signiﬁcant increase in the number of
nonviable cells was evident on treatment (P<0.01) when
compared to tumor controls. Mean survival time showed
twofold increase in PST001 + CTX-treated group (P<0.01)
and signiﬁcant increase was observed in the other groups
also.Asigniﬁcantincreaseinsurvivalofthemicewasnoticed
as obtained from percentage ILS (Figure 2(b)). In the groupThe Scientiﬁc World Journal 7
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Figure 3:EﬀectofPST001inTumorVolumereductionandIncreaseinlifespanofvariousgroupsadministeredinEACtumorbearingmice.
Statistically signiﬁcant diﬀerences are at ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001; ns is the non-signiﬁcant, as compared with control group.
treated with PST001 + CTX pretreatment group, a life span
increase of 134.78% was observed (Tables 2 and 3).
3.2.2. Eﬀect of PST001 on EAC Tumor Bearing Mice. Packed
cell volume and tumor cell counts were signiﬁcantly reduced
(P<0.01) in all the PST001-treated groups, and nonviable
cells were increased (P<0.01) when compared to tumor
controls. In the case of EAC also, tumor volume and body
weight were signiﬁcantly reduced than the control in all the
groups with PST001 and PST001 + 5-FU posttreatment (P<
0.01)andinthepretreatmentgroup(P<0.01)(Figure 3(a)).
Mean survival time showed a signiﬁcant enhancement in the
pretreated group (P<0.01). The percentage increment of
life span (Figure 3(b)) of mice treated with PST001 and 5-
FU + PST001 (co-administration) was higher than that of
5-FU. In the 5-FU + PST001-coadministered group, the %
ILS increased to 180 days which was signiﬁcantly higher than8 The Scientiﬁc World Journal
Table 2: Tumor and hematological characteristics in mice injected with DLA on day 1 followed by PST001/drug administration for 14 days
and dissected on 15th day (Group 2).
Concentration DLA control PST 200mg/kg CTX 50mg/kg PST + CTX
Tumor volume (mL) 9 ± 0.3 4.5 ±0.29∗∗∗ 4 ± 0.18∗∗∗ 3.9 ±0.23∗∗∗
Body weight (g) 30.56 ±2.22 8 .32 ±1.5∗∗ 26.8 ±2.5∗∗ 25.7 ±1.1∗∗∗
PCV (mL) 3 ± 0.24 1.2 ±0.1∗∗∗ 0.8 ± 0.1∗∗∗ 0.7 ±0.09∗∗∗
Mean survival time (Days) 20 ± 13 1 ± 2∗∗∗ 35 ± 1∗∗∗ 37 ± 2∗∗∗
% Increase in life span (ILS) — 55 ± 1.4∗∗∗ 75 ± 0.96∗∗∗ 85 ± 1.7∗∗∗
Tumor cell count (106 cells/mL) 150 ± 1.7 45 ± 1∗∗∗ 33 ± 0.95∗∗∗ 32 ± 0.62∗∗∗
Percentage of viable cells 92 ± 17 7 ± 2∗∗∗ 72 ± 1∗∗∗ 70 ± 2.6∗∗∗
Percentage of nonviable cells 8 ± 12 3 ± 1.7∗∗∗ 28 ± 2∗∗∗ 30 ± 1.7∗∗∗
Hb (G%) (12.2–16.2) gm/dL 9 ± 0.26 10.8 ±0.4∗ 11 ± 0.23∗∗ 11.5 ±0.3∗∗
RBC (Million/cmm) (7–12.5) × 106/mm3 3.3 ±0.23 .9 ±0.45ns 4 ±0.18ns 4.2 ±0.6ns
TC (c/mm) (5100–11600) 12000 ± 507 9700 ± 360∗∗∗ 9000 ± 264∗∗∗ 8500 ± 300∗∗∗
Platelets (/cmm) (160000–410000) 150000 ± 1322 200000 ± 264∗∗∗ 205000 ±1479∗∗∗ 215000 ± 500∗∗∗
Data were expressed as mean ± SD (n = 6) on day 15 of the experiment. Statistically signiﬁcant diﬀerences are at ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001; ns is
the nonsigniﬁcant, as compared with control group.
Table 3: Tumor and hematological characteristics in mice injected with drug for 7 days, DLA administered on 8th day, observed for 21 days,
and dissected on 22nd day (Group 4).
Concentration DLA control PST 200mg/kg CTX 50mg/kg PST + CTX
Tumor volume (mL) 9 ± 0.5 4 ± 0.61∗∗∗ 3.6 ±0.96∗∗∗ 3.1 ±0.58∗∗∗
Body weight (g) 35.12 ±1.53 1 .59 ± 2.3∗ 28.97 ±1.3∗∗ 26.8 ±1.4∗∗
PCV (mL) 3.1 ±0.60 .9 ±0.05∗∗∗ 0.8 ±0.05∗∗∗ 0.6 ±0.07∗∗
Mean survival time (Days) 23 ± 0.87 38 ± 0.99∗∗∗ 43 ± 0.91∗∗∗ 54 ± 1∗∗∗
% Increase in life span (ILS) — 65.21 ±0.67∗∗∗ 86.95 ±0.83∗∗∗ 134.78 ±0.79∗∗∗
Tumor cell count (106 cells/mL) 147 ± 0.21 42 ± 0.6∗∗∗ 28 ± 0.95∗∗∗ 25 ± 0.3∗∗∗
Percentage of viable cells 94 ± 17 3 ± 1.7∗∗∗ 68 ± 2∗∗∗ 64 ± 2∗∗∗
Percentage of nonviable cells 6 ± 12 7 ± 2∗∗∗ 32 ± 1∗∗∗ 36 ± 2∗∗∗
Hb (G%) (12.2–16.2) gm/dL 7.9 ±0.36 8.3 ±0.36ns 9.6 ±0.79∗ 12.6 ±0.79∗∗∗
RBC (Million/cmm) (7–12.5) × 106/mm3 2.7 ±0.72 2.8 ±0.65ns 3.3 ± 0.6ns 4.6 ±0.72∗
TC (c/mm) (5100–11600) 16900 ± 360 12400 ± 300∗∗∗ 10500 ± 150∗∗∗ 9000 ± 100∗∗∗
Platelets (/cmm) (160000–410000) 135000 ± 500 150000 ± 430∗∗∗ 195000 ± 600∗∗∗ 210000 ± 550∗∗∗
Data were expressed as mean ± SD (n = 6) on day 22 of the experiment. Statistically signiﬁcant diﬀerences are at ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001; ns is
the non-signiﬁcant, as compared with control group.
the % ILS (73.68 days) when the standard drug 5-FU alone
was administrated (Tables 4 and 5).
3.2.3. Hematological Parameters in DLA and EAC Tumor
Bearing Mice. Hematological parameters in DLA and EAC
tumor bearing mice on day 15 and 22 were found to be
signiﬁcantly altered when compared to the normal group.
The total WBC count was found to be signiﬁcantly increased
in the untreated tumour bearing animals with a reduction
in Hb content, RBC and platelet count (Tables 2 and 4).
In a diﬀerential count of the WBC, an increase in the
percentage of neutrophils and reduction in the percentage of
lymphocytes was observed in these animals. Administration
of PST001 200mg/kg and PST + CTX/5-FU treatment
restored all the altered hematological parameters to almost
near to normal values (Tables 2–5).
3.3. Evaluation of Immunomodulatory Properties of PST001
3.3.1. Lymphocyte Proliferation Assay. Enhancement of lym-
phocyte proliferation in PST001-administered normal mice
was signiﬁcant in comparison with that of control group.
In vitro lymphocyte proliferation index (LPI) was 1.51 in
200mg/kg concentration of PST001 at 0hr in comparison
with control mice in the absence of PHA and in the presence
of PHA lymphocyte proliferation index was increased up
to 1.83. After 72hrs incubation, 200mg/kg PST001-treated
samples showed an LPI of 1.73 in the absence of PHA, and in
the presence of PHA, LPI was 1.95 as shown in Figure 4.
3.3.2.EﬀectofPST001onHaematologicalParameters. Haem-
atological markers like total count and platelet count were
remarkably increased as shown in Table 6 in PST001-treatedThe Scientiﬁc World Journal 9
Table 4: Tumor and hematological characteristics in mice injected with EAC on day 1 followed by drug administration for 14 days and
dissected on 15th day (Group 2).
Concentration EAC control PST 200mg/kg 5-FU 20mg/kg PST + 5-FU
Tumor volume(mL) 10.2 ±0.72 4.8 ±0.26∗∗∗ 3.9 ±0.13∗∗∗ 3.4 ±0.1∗∗∗
Body weight (g) 31.82 ±1.52 9 .14 ±2.3∗ 27.47 ±1.7∗∗ 26.23 ±2.5∗∗
PCV(mL) 3.1 ±0.26 1.4 ±0.26∗∗∗ 0.9 ±0.21∗∗∗ 0.7 ±0.13∗∗∗
Mean survival time (Days) 19 ± 0.98 28 ± 0.99∗∗∗ 33 ± 1∗∗∗ 38 ± 1.7∗∗∗
% Increase in life span (ILS) — 47.3 ±0.84∗∗∗ 73.68 ±0.93∗∗∗ 100 ± 1∗∗∗
Tumor cell count (106cells/mL) 175 ± 25 8 ± 1∗∗∗ 39 ± 1.3∗∗∗ 32 ± 1∗∗∗
Percentage of viable cells 93 ± 17 5 ± 2∗∗∗ 70 ± 0.5∗∗∗ 68 ± 1∗∗∗
Percentage of nonviable cells 7 ± 12 5 ± 0.57∗∗ 30 ± 2∗∗ 32 ± 1∗∗∗
Hb (G%) (12.2–16.2) gm/dL 11 ± 0.5 12 ±1ns 12.2 ±0.8ns 12.4 ±0.6ns
RBC (Million/cmm) (7–12.5) × 106/mm3 3.6 ± 14 .2 ±1.2ns 4.3 ±0.5ns 4.4 ±1ns
TC (c/mm) (5100–11600) 17500 ± 600 10100 ± 550∗∗∗ 9300 ± 300∗∗∗ 8200 ± 150∗∗∗
Platelets (/cmm) (160000–410000) 203000 ± 150 250000 ± 235∗∗∗ 301000 ± 195∗∗∗ 350000 ± 210∗∗∗
Data were expressed as mean ± SD (n = 6) on day 15 of the experiment. Statistically signiﬁcant diﬀerences are at ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001; ns is
the non-signiﬁcant, as compared with control group.
Table 5: Tumor and hematological characteristics in mice injected with drug for 7 days, EAC administered on 8th day, observed for 21 days
and dissected on 22nd day (Group 4).
Concentration EAC Control PST 200mg/kg 5-FU 20mg/kg PST + 5-FU
Tumor volume (mL) 9.7 ±0.24 .4 ±0.34∗∗∗ 3.3 ± 0.6∗∗∗ 2.9 ±0.29∗∗∗
Body weight (g) 34.91 ±1.93 0 .8 ±1.2∗∗ 26.21 ±2.3∗∗ 25.12 ±2.7∗∗
PCV (mL) 3 ± 0.45 1.2 ±0.1∗∗∗ 0.8 ± 0.1∗∗∗ 0.6 ±0.2∗∗∗
Mean survival time (Days) 20 ± 13 3 ± 2∗∗∗ 44 ± 0.57∗∗∗ 56 ± 1∗∗∗
% Increase in life span (ILS) — 65 ± 1∗∗∗ 120 ± 2∗∗∗ 180 ± 1∗∗∗
Tumor cell count (106 cells/mL) 173 ± 0.43 51 ± 0.36∗∗∗ 29 ± 0.5∗∗∗ 25 ± 0.36∗∗∗
Percentage of viable cells 92 ± 17 0 ± 2∗∗∗ 64 ± 0.57∗∗ 60 ± 1∗∗
Percentage of nonviable cells 8 ± 13 0 ± 0.57∗∗∗ 36 ± 1∗∗∗ 40 ± 2∗∗∗
Hb (G%) (12.2–16.2) gm/dL 7.2 ±0.89 .8 ±1∗ 12 ± 1.4∗∗∗ 14 ± 1.9∗∗∗
RBC (Million/cmm) (7–12.5) × 106/mm3 2.7 ±0.43 .6 ±0.9ns 4.3 ± 1.3ns 5.1 ±1.6∗∗
TC (c/mm) (5100–11600) 18800 ± 100 11100 ± 50∗∗∗ 8500 ± 75∗∗∗ 8000 ± 60∗∗∗
Platelets (/cmm) (160000–410000) 115000 ± 450 170000 ± 525∗∗∗ 200000 ± 550∗∗∗ 230000 ± 490∗∗∗
Data were expressed as mean ± SD (n = 6) on day 22 of the experiment. Statistically signiﬁcant diﬀerences are at ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001; ns is
the non-signiﬁcant, as compared with control group.
normal mice, which support the immunomodulatory prop-
erty of the compound.
3.3.3. Immunophenotyping. Immunophenotyping for lym-
phocytesubsetswithCDmarkersshowedsigniﬁcantincrease
in the proportion of T lymphocyte population in the PST001
treated mice. The increase was prominent in the CD4+
cells (Table 7) and showed an increased CD4/CD8 ratio.
The CD4/CD8 ratio was highest in Group II (100mg/Kg)
and found to decline with higher concentrations of the
compound showing dose-dependant activity of PST001.
Immunophenotyping was done in a combination of CD3
and CD4 and CD3 and CD8 format. In a CD3/CD4 and
CD3/CD8scatterplot,lowerrightandupperrightquadrants
indicated CD4 and CD8 positive cells (Figures 5(a)–5(d)),
respectively. It was found that 100mg/Kg concentration
of PST001 signiﬁcantly enhanced CD4 count (55.55%) in
comparison with control group (36.30%).
3.3.4. Eﬀect of PST001 on Bone Marrow Cellularity. Bone
marrow cellularity also showed an increase at concentrations
100mg/kg and 200mg/kg body weight when compared to
that in controls (Table 8).
3.4. Toxicity Studies
3.4.1. Eﬀect of PST001 on Acute Toxicity. Intraperitoneal
administration of PST001 from 500mg/kg to 2000mg/kg
body weight did not induce any toxic eﬀect as evidenced by
absence of signiﬁcant behavioral changes and LD50 could
not be calculated as there was no death of animals.10 The Scientiﬁc World Journal
Table 6: Eﬀect of PST001 on haematological parameters in mice.
Control 100mg/kg PST001 200mg/kg PST001 400mg/kg PST001
(1) Hb (g/dL) 12.8 ±0.25 13.4 ±0.84ns 12.3 ±1.13ns 12.1 ±1.41ns
(2) Total WBC count (cells/mm3) 5,100 ± 212 9,100 ± 141∗∗∗ 8400 ± 176∗∗∗ 8300 ± 127∗∗∗
(3) Diﬀerential count
(1) Polymorphoneutrophils (%) 50 ± 2.82 45 ± 2.12 ∗∗ 42 ± 1.41∗∗∗ 41 ± 1.13∗∗∗
(2) Lymphocytes (%) 47 ± 2.40 52 ± 1.41∗ 54 ± 2.26∗∗∗ 55 ± 2.54∗
(3) Eosinophils (%) 3 ± 0.70 3 ± 0.28∗ 4 ± 0.42∗ 4 ± 0.84∗∗∗
(4) Platelet (cells/mm3) 3,40,000 ± 282 3,53,000 ± 777∗∗∗ 3,62,000 ± 707∗∗∗ 3,83,000 ± 636∗∗∗
(5) RBC (Cells/Ml × 106)4 .7 ±0.07 4.9 ±0.08∗∗∗ 5.1 ±0.02∗∗∗ 5.4 ±0.04∗∗∗
Data were expressed as mean ± SD (n = 6) on day 15 of the experiment. Statistically signiﬁcant diﬀerences are at ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001; ns
is non-signiﬁcant, when compared between control, 100mg/kg PST001, 200mg/kg PST001, and 400mg/kg PST001 using Tukey’s multiple comparison’s test
(Graph Pad Prism 4.0). Hb: Hemoglobin; RBC: Red Blood Corpuscles.
Table 7: Table showing the eﬀect of PST001 on lymphocyte subsets.
Concentration CD3 CD4 CD8 CD4/CD8 ratio
Control 59.51 ±1.42 36.30 ±0.84 20.17 ±0.66 1.799
100mg/kg 57.01 ±1.0∗∗ 55.55 ±0.91∗∗∗ 27.08 ±1.01∗∗∗ 2.05
200mg/kg 41.83 ±0.94∗∗∗ 38.96 ±0.48∗∗∗ 20.28 ±0.53 ns 1.92
400mg/kg 31.69 ±0.62∗∗∗ 30.48 ±0.66∗∗∗ 22.62 ±0.39∗∗∗ 1.34
Data were expressed as mean ± SD (n = 6) on day 15 of the experiment. Statistically signiﬁcant diﬀerences are at ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001; ns is
the non-signiﬁcant, as compared with control group.
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Figure 4: In vitro Lymphocyte Proliferative activity after 14 days
PST001 treatment in 72 hours of incubation period. Data were
expressed as mean ± SD (n = 6). Statistically signiﬁcant diﬀerences
are at ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001; ns is the non-
signiﬁcant, as compared with control group.
3.4.2. Eﬀect of PST001 on Subacute Toxicity. Since no animal
death was observed up to 2000mg/kg body weight and
LD50 could not be calculated, doses for subacute toxicity
were calculated as 1/20th, 1/10th, and 1/5th of 2000mg/kg.
Histopathology results showed no evidence of signiﬁcant
cellular abnormalities in PST001-treated mice. Kidneys with
normal glomeruli, normal looking tubules lined by normal
cells, liver showing normal hepatocytes, and spleen showing
normal white pulp and red pulp areas were observed. Up
Table 8: Eﬀect of PST001 on bone marrow cellularity.
Concentration of PST001
in mg/kg
Number of live cells/femur
in 1mL × (106)
Control 12 ±0.56
100mg/kg 12.4 ±0.42 ns
200mg/kg 14.4 ±0.49∗∗∗
400mg/kg 12.8 ±0.39∗
Data were expressed as mean ± SD (n = 6) on day 15 of the experiment.
Statistically signiﬁcant diﬀerences are at ∗P<0.05, ∗∗P<0.01, ∗∗∗P<
0.001; ns is the non-signiﬁcant, as compared with control group.
to a concentration of 200mg/kg organs were found to be
normal. At a concentration of 400mg/kg atrophic and mild
degenerative changes were observed in kidneys and slight
necroticchangesofhepaticcellswereobserved(Figures6(a)–
6(e)). Body weight was found to be unaltered. The mice were
found to exhibit normal behavior following withdrawal of
the drug.
Biochemical parameters like SGPT, SGOT, Blood Urea,
and Serum Creatinine were found to be in the normal range
(Table 9).
4. Discussion
A wide range of biologically active polysaccharides are iso-
lated from higher plants and a number of them are reported
to have antitumor and immunomodulatory activities. The
mechanisms that mediate the biological activity of polysac-
charides are still not clearly understood. Polysaccharides
from natural resources usually do not attack cancer cellsThe Scientiﬁc World Journal 11
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Figure 5: (a–d) Eﬀect of PST001 on lymphocyte subsets by immunophenotyping. (a) CD3 and CD4 in control mice, (b) CD3 and CD4 in
100mg/kg PST001-treated mice, (c) CD8 in control mice, and (d) CD8 in 100mg/kg PST001-treated mice.
directly but produce their antitumor eﬀects by activating dif-
ferent immune responses in the host. The antitumor action
of polysaccharides requires an intact T-cell component; their
activity is mediated through a thymus-dependent immune
mechanism [14].
The present study investigated the therapeutic potential
of a polysaccharide PST001 isolated and puriﬁed from the
seed kernel of Tamarindus indica In an earlier study, we
have reported the in vitro immunomodulatory activities
such as phagocytic enhancement and inhibition of leukocyte
migrationinnormalcellsalongwithantiproliferativeactivity
on cancer cells induced by this polysaccharide [6]. Tamarind
seed polysaccharide has been tested in B6C3F1 mice with
results demonstrating the absence of carcinogenicity in mice
of either sex following long-term dietary exposure by Sano
et al. [15].
The antitumor activity of PST001 polysaccharide in
DLA/EAC tumors has been evaluated. It was observed that at
the dose of 200mg/kg body weight concentration of PST001
signiﬁcantly reduced the tumor volume, packed cell volume,
and tumor (viable) cell count and restored haematological
parameters to nearly normal levels. In untreated DLA/EAC
tumor bearing mice, a regular rapid increase in ascitic tumor
volume was observed. Ascitic ﬂuid is the direct nutritional12 The Scientiﬁc World Journal
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Figure 6: Light micrographs of H- & E-stained sections of formalin-ﬁxed sections of control and 200mg/kg PST001-treated mice. (a)
Control kidney, (b) 200mg/kg PST001-treated Kidney, (c) Control Liver, (d) 200mg/kg PST001 treated liver, (e) Control Spleen, and (f)
200mg/kg PST001 treated spleen.
Table 9: Eﬀect of PST001 on biochemical parameters in mice.
Normal range Control 100mg/kg PST001 200mg/kg PST001 400mg/kg PST001
(1) Blood Urea (mg%) 5–40 30 ± 2.12 34 ± 0.70∗∗∗ 25 ± 0.98∗∗∗ 29 ± 1.13ns
(2) Serum Creatinine (mg%) 0–1.2 1.1 ±0.02 1.0 ±0.14ns 0.7 ±0.07
∗∗∗ 0.8 ±0.09
∗∗∗
(3) SGOT (IU/L) 8–40 47 ± 1.41 28 ± 0.70∗∗∗ 30 ± 0.42∗∗∗ 31 ± 0.84∗∗∗
(4) SGPT (IU/L) 5–35 10 ± 1.27 13 ± 0.84∗∗∗ 11 ± 0.70ns 9 ± 0.42ns
Data were expressed as mean ± SD (n = 6) on day 15 of the experiment. Statistically signiﬁcant diﬀerences are at ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001; ns
is non-signiﬁcant, when compared between control, 100mg/kg PST001, 200mg/kg PST001, and 400mg/kg PST001 using Tukey’s multiple comparison’s test
(Graph Pad Prism 4.0). SGOT: Serum Glutamate Oxaloacetate Transaminase, SGPT: Serum Glutamate Pyruvate Transaminase.
source for tumor cells and a rapid increase in ascitic ﬂuid
with tumor growth would be a means to meet the nutritional
requirement of tumor cells [16]. Treatment with PST001
reduced the tumor volume, viable tumor cell count, and
body weight and increased the life span of tumor bearing
mice. The reliable criteria for judging the value of any
anticancer drug are the prolongation of life span of animals
[17]. These results are thus suggestive of PST001 by a reduc-
ing eﬀect on the nutritional ﬂuid formation and arresting
the tumor growth and thus increasing the life span of
DLA/EAC-bearing mice by PST001. As per the NCI criteria,
an ILS exceeding 25% indicates that the drug has signiﬁcant
antitumor activity [18]. This suggests that PST001 has
potent antitumor activity against DLA/EAC bearing mice.
Also it was observed that PST001 is an excellent anticancer
agent in combination therapy when administered along with
conventional anticancer agents like CTX and 5-FU.
In cancer chemotherapy, the major problems that are
being encountered are of myelosuppression and anemia
[19, 20]. The anemia encountered in tumor bearing miceThe Scientiﬁc World Journal 13
is mainly due to reduction in RBC or hemoglobin content,
and this may occur either due to iron deﬁciency or due to
hemolytic or myelopathic conditions [21]. Treatment with
PST001 restored the hemoglobin (Hb) content, RBC, and
WBC counts more or less to normal levels indicating that
PST001 possess, stimulating action on the hematopoietic
system. PST001 alone showed good antitumor eﬀects but in
combination with conventional chemotherapeutic agents it
showed an increased activity. Reduced tumor induction after
administering PST001 for 7 days clearly demonstrated the
chemopreventive eﬀect of this polysaccharide.
Antitumor polysaccharides are generally immunomodu-
lators and the immunomodulatory property of PST001 was
reported by us earlier. The aim of immunoadjuvant therapy
is to stimulate the innate and adaptive immune systems to
overcome the immunosuppressive situation in cancer which
is usually the side eﬀect of the conventional modes of cancer
treatments, such as surgery, radiotherapy or chemotherapy.
PST001 pretreatment resulted in combating the immuno-
suppression haematological and immunological parameters
in DLA/EAC tumor bearing animal group coadministered
with CTX/5-FU. Thus, in vivo treatment with this polysac-
charide accelerates the recovery of immunosuppressed mice
from leukopenia, myelosuppression, and immunosuppres-
sion, the common conditions associated with cancer chemo-
therapy along with signiﬁcant tumor reduction and in-
creased survival.
PST001 prophylactically enhanced haemoglobin (Hb),
red blood cells (RBCs), white blood cells (WBCs), and
platelets in normal mice indicating hematopoietic proper-
ties. In vitro lymphocyte transformation assay is a typical
immune reaction with the mechanism well understood. This
assay has been extensively used as an immune parameter
to investigate lymphocyte responsiveness because of its high
sensitivity [22]. A dose of 200mg/kg body weight concen-
tration of PST001 induced a higher rate of lymphocyte pro-
liferation than any other concentration. Decreased activity
above 200mg/kg concentration indicated that 200mg/kg is
the threshold dose for polysaccharide PST001 to act as an
immunomodulating agent.
ThediﬀerentsubpopulationsofT-cells[23] are recogniz-
ed largely by their expression of surface proteins (CD mark-
ers). All T-cells express CD3, a hetero-oligomeric protein
that is part of T-cell receptor complex, and could be further
subdivided in to those cells that express CD4+ and those that
express CD8+. CD4+ and CD8+ populations which include
the helper and cytotoxic cells were increased at 100mg/kg
concentrationofPST001.TheincreasedexpressionsofCD4+
and CD8+ cells suggested a strong predominance of TH1
cytokine producing T cells on treatment with PST001.
Bone marrow is a site of continued proliferation and
turnover of blood cells and is a source of cells involved in
immune reactivity [24]. A high degree of cell proliferation
renders bone marrow a sensitive target, particularly to
cytotoxic drugs. Increase in bone marrow cellularity at
100mg/kg and 200mg/kg concentrations was observed with
PST001, and above 200mg/kg concentrations, the count of
bone marrow cells decreased indicating that 100mg/kg and
200mg/kg concentrations are the active doses of PST001.
For the past several decades, attempts have been made to
search for safer immunomodulating agents, and one of the
special focuses has been on the biological response modiﬁers
(BRMs) derived from natural products.
In this study, toxicological evaluations were also made
to investigate the toxicity of polysaccharide PST001. Acute
toxicity results proved that there was no toxicity up to a
concentration of 2000mg/kg body weight in Balb/c mice
as evidenced by absence of animal death. Subacute toxi-
city experiments with doses 1/20th, 1/10th, and 1/5th of
2000mg/kg concentration of PST001 showed that there was
only slight degenerative changes in liver and kidney after the
administration of PST001 for 14 days at higher doses. SGOT
(AST) and SGPT (ALT) are enzymes that are made almost
exclusively by liver cells. ALT and AST are considered to be
sensitive indicators of hepatocellular damage, and the values
provide a quantitative evaluation of the degree of damage
to the liver [25]. In the present study, the liver and kidney
functions can be interpreted to be unaﬀected as the enzyme
values are within the normal range. A mild toxicity could
be observed at higher doses in kidney and liver might be
reversible upon discontinuation of the compound evidenced
by the normal behavior of the retained mice.
Fromthepresentstudyandtheearlierreports,itwassug-
gested that PST001 could be developed as an adjuvant for
cancer management after conducting clinical trials in human
subjects. Also the eﬀectiveness of PST001 as a cancer vac-
cine can be evaluated based on the aforementioned results.
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